Aviv Pharma Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$2M
Investors
12
Min Invest
$25,000
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Aviv Pharma Inc. is a Nevada corporation that filed a Form D with the SEC on December 28, 2023 in the Pharmaceuticals industry group. The offering claims Rule 506(c) and covers equity. Aviv Pharma Inc. reported $2,252,517 sold from 12 investors of a $4,000,000 total offering as of the Form D filed December 28, 2023. The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $25,000. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. The issuer's address of record is 401 Ryland Street, Suite 200a, Reno, NV 89502.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
0
none on file
Critical / warning
0 / 0
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
lapsed
Investor
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Philip Arthur Epstein
Executive Officer, Director · Reno, NV
Jeffrey Alan Glazer
Executive Officer, Director · Reno, NV
Ricardo Alberto Hungria
Director · Reno, NV
Robert Rene Rabalais
Director · Reno, NV
Jeffrey David Rosenberg
Director · Reno, NV
Questions About Aviv Pharma Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Aviv Pharma Inc.?
Aviv Pharma Inc. is a Nevada corporation that filed a Form D with the SEC on December 28, 2023 in the Pharmaceuticals industry group. The filing claims Rule 506(c) for an offering of equity.
Is Aviv Pharma Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. Aviv Pharma Inc. filed a Form D with the SEC on December 28, 2023 claiming Rule 506(c). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $2,252,517 sold to 12 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Aviv Pharma Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Aviv Pharma Inc. claimed Rule 506(c) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Aviv Pharma Inc. raised?
Aviv Pharma Inc. reported $2,252,517 sold from 12 investors of a $4,000,000 total offering as of the Form D filed December 28, 2023.
Who can invest in Aviv Pharma Inc.?
The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $25,000.
What is the minimum investment in Aviv Pharma Inc.?
The Form D lists $25,000 as the minimum investment accepted from any outside investor as of December 28, 2023. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling Aviv Pharma Inc. and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.
Who is behind Aviv Pharma Inc.?
The Form D lists 5 related persons: Philip Arthur Epstein, executive officer, director; Jeffrey Alan Glazer, executive officer, director; Ricardo Alberto Hungria, director; Robert Rene Rabalais, director; Jeffrey David Rosenberg, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Aviv Pharma Inc. located?
The issuer's address on its SEC filings is 401 Ryland Street, Suite 200a, Reno, NV 89502. Its phone number of record is 9179130408. It is organized under the laws of Nevada.
How long is the Aviv Pharma Inc. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
What is Aviv Pharma Inc.'s revenue?
The Form D reports a revenue range of No Revenues.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.